S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
| Autor: | Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Hyo Song Kim, Minkyu Jung, Kyung Hee Lee, Inkyung Jung, Moon Hee Lee, Sung Hoon Noh, Bong Seog Kim, Dong Bok Shin, Woo Jin Hyung, Jae Ho Cheong, Sun Young Rha, Hyun Cheol Chung, Choong-kun Lee |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty Adjuvant chemotherapy Stomach neoplasms Docetaxel 03 medical and health sciences 0302 clinical medicine Gastrectomy Internal medicine Antineoplastic Combined Chemotherapy Protocols Republic of Korea medicine Humans Aged Tegafur Cisplatin S-1 based doublet Dose-Response Relationship Drug business.industry Stage III Gastric Cancer Middle Aged Survival Analysis Drug Combinations Oxonic Acid Treatment Outcome 030104 developmental biology Chemotherapy Adjuvant Stage III 030220 oncology & carcinogenesis Female Original Article business medicine.drug |
| Zdroj: | Cancer Research and Treatment : Official Journal of Korean Cancer Association |
| ISSN: | 2005-9256 1598-2998 |
| Popis: | Purpose We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients. Materials and Methods Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m2/day on days 1-14 plus docetaxel 35 mg/m2on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m2/day on days 1-14 plus cisplatin 60 mg/m2on day 1) every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate. Results Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was approved based on the CLASSIC study, itwas decided to close the study early. With a median follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not significantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4 adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned treatment. Conclusion Our findings suggest that SP or DS is an effective and tolerable option for patients with curatively resected stage III gastric cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|